SCHEMBL25781520

SCHEMBL25781520

CCn1nnc(-c2ccccc2Nc2ccc(Cl)c(Cl)c2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 5/20 0.49
▸ ALDH1A1 P00352 6/20 0.48
▸ LMNA P02545 3/20 0.48
▸ MEN1 O00255 5/20 0.47
▸ KMT2A Q03164 5/20 0.47
▸ HPGD P15428 4/20 0.47
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ HSD17B10 Q99714 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.44
▸ MAPT P10636 2/20 0.43
▸ TP53 P04637 2/20 0.41
▸ POLB P06746 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ GPR55 Q9Y2T6 1/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ GUSB P08236 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ USP2 O75604 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20552254 0.88 TP53 (0.42) TSHRALDH1A1LMNAMEN1KMT2A
SCHEMBL25788798 0.85 TSHR (0.47) TSHRALDH1A1LMNAMEN1KMT2A
SCHEMBL25786481 0.83 TSHR (0.49) TSHRALDH1A1LMNAMEN1KMT2A
SCHEMBL25786372 0.81 TSHR (0.49) TSHRALDH1A1LMNAMEN1KMT2A
SCHEMBL25786389 0.81 TSHR (0.49) TSHRALDH1A1LMNAMEN1KMT2A
SCHEMBL20553127 0.78 TSHR (0.41) TSHRALDH1A1MEN1KMT2AHPGD
SCHEMBL20553075 0.76 DDX3X (0.42) TSHRMEN1KMT2AHPGDSMN1; SMN2
SCHEMBL25786557 0.76 TSHR (0.56) TSHRALDH1A1LMNAMEN1KMT2A
SCHEMBL25781521 0.76 ALDH1A1 (0.42) TSHRALDH1A1LMNAMEN1KMT2A
SCHEMBL25786548 0.76 TSHR (0.44) TSHRALDH1A1LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-22 — — US disclosed
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF TEAD1, TEAD4, TEAD2 TSHR 2680/4885ALDH1A1 3323/4885LMNA 2451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback